ESR1 and breast cancer: 294 for excellent review). A recent systematic review exploring 19 studies with a total of 7693 women found AR expression in 60.5% of breast cancers. AR expression was more common in ERα-positive tumors (74.8%) compared to ER-negative (31.8%), and patients expressing AR had improved overall survival (295).